



The Digital Examiner
www.prostaaid.org

“Issue #301” January 2025



HAPPY NEW YEAR

Wishing you a year filled with new hopes,
joys, and beginnings.

PROSTAID CALGARY

Upcoming Events

General Meeting

There will be no general meeting in January

Our next general meeting will be held on February 19th. Our guest speaker will be Scott Patterson from Wellsprings Alberta.



Warriors Lunch

Our next lunch meeting for the warriors is Tuesday January 7th 2025. The location is the CKE community center located at 1015 73 Ave SW Calgary starting at 11:30 am.

If you would like to attend, please RSVP so we can order the right amount of Pizza.

RSVP HERE >> jim.richardson@telus.net

We will send out a reminder in early January.

All of our monthly General meetings are in person or via Zoom

Location for in person is:

CKE Community Centre (1015 73 Ave SW, Calgary, AB).
Everyone is welcome

If you are interested in attending via Zoom please sign up [HERE](#)

Exciting Opportunity Alert! Prostaïd Calgary is on the lookout for passionate individuals eager to make a real difference. Join us as a Board Member and play a vital role in our impactful mission. Your skills and dedication can help shape a brighter future. "If you believe this is the perfect opportunity for you, we'd love to hear from you!

Reach out to any of our Board members or connect with me directly at program.director@prostaïd.org.

Connect With Us

Information
Phone 403 455 1916
info@prostaïd.org
Brad Sterling
President
president@prostaïd.org

[Connect With Us](#)

Support Groups

Jim Richardson
403 370 1514
Warriors
jim.richardson@telus.net
Wives, Partners & Caregivers
Newly Diagnosed
info@prostaïd.org

[Meeting Info Here](#)



Donate Today

PROSTAID Calgary is a registered charity that relies on the generosity of its members, supporters and friends to achieve its goals. Tax receipts are issued for all amounts over \$20.00.

Your donations are used to support our monthly journal (the Digital Examiner), our free online video library, our website, our outreach programs and general awareness.

[Donate Today](#)

Articles Of Interest



DRIVING CHANGE FOR MEN'S HEALTH

The MAN VAN® is Canada's first and only mobile men's health clinic offering FREE PSA (Prostate Specific Antigen) blood testing used for early detection of prostate cancer.

Now serving Edmonton & north for men 40 to 70 and for men between 40 and 49 please go to Get Checked for specific details.

- No appointment necessary
- Find the next community clinic near you
- 15 minutes can save your life!

[MAN VAN UPCOMING CLINICS](#)


A New Treatment For Prostate Cancer

Novartis Pharmaceuticals Canada has successfully negotiated with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection), a new treatment for prostate cancer. This milestone, announced on December 13, 2024, paves the way for broader access, though patients will still need to wait for inclusion in provincial and territorial formularies.

PLUVICTO™ targets prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients who have already undergone other treatments. The therapy combines a targeting compound with a radioactive particle to deliver precision cancer treatment, potentially offering hope to those with limited options.

Healthcare professionals and patient advocacy groups view the agreement as a major step forward for patients, particularly those with advanced prostate cancer who have exhausted other treatments. Novartis is committed to working with local drug programs to ensure rapid access to this important therapy.

[Full Article Here](#)




Researchers find new way to 'starve' prostate cancer tumors at the cellular level

New research by a team of Indiana University School of Medicine scientists and their collaborators has uncovered a novel vulnerability in prostate cancer animal models that starves prostate tumors of critical nutrients and stunts their growth, which could lead to the development of new treatments for the deadly disease..

December 2024
MedicalXpress

[Starve](#)



Putting the brakes on prostate cancer cells: Androgen receptor can alter normal prostate growth


A protein called the androgen receptor normally functions to guide the development of the prostate—signaling the cells to stop growing, act as normal prostate cells and maintain a healthy state. The receptor is activated by androgens or sex hormones like testosterone, which triggers the receptor to bind to DNA, causing the expression of some genes and suppression of others.

But in cancer, the androgen receptor is reprogrammed to tell the cells to continue growing, driving tumor development.

[More Info](#)

November 2024
MedicalXpress

[Androgen](#)




Novel platinum complex shows strong antiproliferative effects with low toxicity in preclinical prostate cancer models

Prostate cancer is an androgen-dependent malignancy that presents a marked treatment challenge, particularly after progression to the castration-resistant stage. Traditional treatments such as androgen deprivation therapy often lead to resistance, necessitating novel therapeutic approaches.

Trial Results

December 2024
Phys Org

Novel




FDA grants clearance to NanoKnife System for prostate tissue ablation

The NanoKnife System minimizes the life-altering complications often associated with traditional treatments by selectively targeting prostate tissue while preserving critical functions.

Treatment Options In Canada

December 2024
Urology Times

NanoKnife



JANX007 demonstrates encouraging clinical activity in mCRPC

Updated data from the phase 1a ENGAGER-PSMA-01 trial (NCT05519449) showed safety and encouraging anti-tumor activity of the PSMA-targeting TRACTr JANX007 in the treatment of patients with metastatic-castration resistant prostate cancer (mCRPC).

Trial Results

December 2024
Urology Times

JANX007



Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review

While there was an increasing trend in ADT intensification for mHSPC over the study period across geographies, use remained suboptimal considering the high proportion of patients who were still receiving ADT monotherapy only. These findings highlight the need for interventions to further optimise current mHSPC therapies with high guideline concordance.

More information

November 2024
URO Today

[ADT Use](#)




PET/CT can detect prostate cancer in 'PSA 0' patients

In prostate cancer management, the undetectable PSA level does not guarantee the absence of disease progression, emphasizing the ongoing need for frequent monitoring of the disease with the PSMA PET/CT technique

December 2024
Clinical News

[PET/CT](#)



Better outcomes start from clarity.

When it comes to a cancer diagnosis, Clarity means peace of mind. And when it comes to prostate cancer detection, it takes the right data to deliver that Clarity.

ClarityDX Prostate is a clinically proven decision support tool that uses a machine learning platform to calculate an accurate prostate cancer risk score from clinical data and multiple blood-based PSA test results (5-7).

If you have an elevated PSA, or a suspicion of prostate cancer, ClarityDX Prostate may be right for you. ClarityDX Prostate takes the fear and uncertainty out of prostate cancer screening.

[ClarityDX](#)

Read about these articles below

- 1-Screening Primary Driver of Averted Cancer Deaths
- 2-Helping a co-worker with cancer
- 3-Mindfulness may improve quality of life
- 4-African American men respond more favorably to Ra-223
- 5-The benefits of marine lipids in the fight against cancer
- 6- Impact of Treatment Time on Prostate Cancer Patients
- 7-Testing with MRI Enhances Stratification of Surveillance Patients
- 8-Combining Lutetium-PSMA with Hormonal Therapy
- 9-Canadian Prostate Cancer Guide

For Caregivers & Families



Screening Primary Driver of Averted Cancer Deaths From 1975 to 2020

Over the past 45 years, cancer prevention and screening accounted for most cancer deaths averted for breast, cervical, colorectal, lung, and prostate cancers.

More Info

December 2024
Renal + Urology

Screening




Helping a co-worker with cancer

Relationships between people in the workplace can vary a lot. This can make it especially hard to know how to act or what to say when a co-worker has cancer. Some people may not want to talk about having cancer while at work. They may prefer to focus on their job tasks, rather than on cancer.

Canadian Cancer Society

Helping



Addressing barriers to advance care planning by adults with advanced cancers: Mindfulness may improve quality of life

"Mindfulness practices help individuals increase their mindfulness muscle, so to speak. Anything that we do in our life, from brushing our teeth to having a conversation with a loved one, can be done with mindful focus, with mindful attention."

November 2024
MedicalXpress

Mindfulness

Articles For Everyone



African American men respond more favorably to Ra-223 therapy

Prostate cancer is the second leading cause of cancer-related death and the most common cancer diagnosis for men in the U.S., with the incidence of disease among African American men approximately 70% higher than in Caucasian men. Radium-223 dichloride (Ra-223, Xofigo) is a theranostic agent for treating patients with mCRPC with bone metastases and no visceral metastases.

Xofigo Info

December 2024
Clinical News

Xofigo



Sardines, mackerel and other oily fish: The benefits of marine lipids in the fight against cancer


The world's oceans represent a vast and largely untapped source of biodiversity, offering a high probability for the discovery of unique chemical compounds with therapeutic properties. Among these, bioactive molecules found in marine organisms have shown notable anticancer effects.

More Info

December 2024
MedicalXpress

Sardines

New Videos



Understanding Time Toxicity: Impact of Treatment Time on Prostate Cancer Patients

Ruchika Talwar hosts Daniel Sentana Lledo to discuss the concept of time toxicity in prostate cancer treatment. Time toxicity measures the amount of time patients spend in the healthcare system and how it impacts their survival time gained from therapies.

November 2024
URO Today

Time Toxicity



Integrating Genomic Testing with MRI Enhances Stratification of Surveillance Patients

Mark Sultan and Eric Kim discuss research on predicting prostate cancer progression during active surveillance using Decipher® genomic classifier scores and MRI characteristics. Their study reveals that while both high Decipher® scores and high-risk MRI findings independently predict progression, these markers are weakly correlated, suggesting they capture distinct risk information.

December 2024
URO Today

Genomic




Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment

The discussion explores various combination strategies, including promising results from the ENZA-p trial combining lutetium-PSMA with enzalutamide, which shows notable response rates in first-line mCRPC.

November 2024
URO Today

Lutetium-PSMA



Canadian Prostate Cancer Guide

Resources, guides and tools to help caregivers, survivors and the recently diagnosed get clarity and more. Read empowering stories and share yours with us.

Bringing you the most up to date information in treatments, support, well-being, and more all in one place

We can help you in achieving the support you're looking for. On the Canadian Prostate Cancer Guide website you can look to find the most up to date information on prostate cancer in one place.

Learn More Here

Thank you to our Sponsors and Community Partners



Disclaimer: The PROSTAID Calgary Society website & newsletter provides news and information about prostate issues and activities of the organization. While information is presented about prostate cancer and related issues, it is not intended as a substitute for professional medical advice, diagnosis, or treatment. PROSTAID Calgary Society recommends that you seek the advice of your physician or other qualified health

professionals regarding questions you may have about any medical condition. Topics on PROSTAID Calgary Society's website & newsletter are presented to inform you and we encourage you to seek professional medical advice before starting any treatment.

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



[Unsubscribe](#)